NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Stock Has Average Price Target of $170.00 According to Brokerages

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) has earned an average recommendation of “Moderate Buy” from the six ratings firms that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has issued a hold rating, three have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $170.00.

NRSN has been the subject of several recent research reports. HC Wainwright initiated coverage on NeuroSense Therapeutics in a report on Thursday, September 3rd. They set a “buy” rating for the company. Weiss Ratings cut shares of NeuroSense Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, July 30th.

NeuroSense Therapeutics Price Performance

NRSN stock opened at $3.93 on Friday. NeuroSense Therapeutics has a 12 month low of $3.82 and a 12 month high of $26.64. The firm has a 50 day simple moving average of $8.05 and a 200 day simple moving average of $12.71. The firm has a market cap of $7.47 million, a PE ratio of -0.36 and a beta of 1.66.

Hedge Funds Weigh In On NeuroSense Therapeutics

A hedge fund recently bought a new stake in NeuroSense Therapeutics stock. Yorkville Advisors Global LP acquired a new position in shares of NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 78,000 shares of the company’s stock, valued at approximately $56,160. Yorkville Advisors Global LP owned about 0.21% of NeuroSense Therapeutics as of its most recent filing with the Securities and Exchange Commission. 1.04% of the stock is currently owned by institutional investors.

NeuroSense Therapeutics Company Profile

NeuroSense Therapeutics Ltd. is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases. The company is headquartered in Israel and conducts research aimed at addressing biological mechanisms associated with diseases such as amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and other neurological disorders.

NeuroSense’s leading investigational product is PrimeC, an oral, fixed-dose combination of ciprofloxacin and celecoxib. The therapy is designed to target multiple disease-related pathways, including neuroinflammation and the regulation of RNA processing, and has been evaluated in clinical studies involving patients with ALS.